Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › autoimmune disorders

Autoimmune disorders

13 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for autoimmune disorders

25 trials tracked for autoimmune disorders: 7 in phase 3 or 4 and 4 with published results. The most-cited published study has 587 citations.

25Trials tracked
7Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 3 7 Phase 2 3 Phase 1 9 Other / NA 6
  1. Phase 3 Scleroderma: Cyclophosphamide or Transplantation Completed · 587 cited
  2. Phase 3 Intravenous Immunoglobulin for PANDAS Completed · 124 cited
  3. Phase 3 A Study of LY2127399 in Participants With Systemic Lupus Erythematosus Completed · 73 cited
  4. Phase 3 A Study of LY2127399 in Participants With Systemic Lupus Erythematosus Completed · 42 cited
  5. Phase 3 Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Autoimmune Diseases Treated With Mycophenolate Completed
  6. Phase 3 Evaluation of Therapeutic Plasma Exchange (TPE) Procedure Using the AMICUS Device Completed
Show 19 more trials
  1. Phase 3 Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA) Completed
  2. Phase 2 Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis Completed
  3. Phase 2 Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis Completed
  4. Phase 2 Diamyd Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes Completed
  5. Phase 1 A Safety and Pharmacokinetic (PK) Study of GSK2982772 in Healthy Subjects Completed
  6. Phase 1 A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of TAK-079 in Healthy Participants Completed
  7. Phase 1 A Study to Investigate the Effects of CBP-307 on the Heart Rate-corrected QT Interval (QTc) in Healthy Subjects Completed
  8. Phase 1 A Study to Investigate the Pharmacokinetics (PK) of Modified Release (MR) Prototype Coated Tablet Formulations of GSK2982772 Completed
  9. Phase 1 A Study of the Safety, Tolerability, Pharmacokinetics and Food Effect After Single and Multiple Ascending Oral Doses Completed
  10. Phase 1 Human Absorption, Distribution and Metabolism Study (hAME) [14C]-KD025 Completed
  11. Phase 1 Phase I Study of GSK2982772 in Japanese Healthy Male Participants Completed
  12. Phase 1 A Study to Compare the Pharmacokinetics (PK) of GSK2982772 Following Administration of Different Modified Release (MR) Formulations in Capsule and MR Tablet Formulations Relative to an Immediate Release (IR) Tablet Formulation and to Check the PK of MR Formulation in Capsule Following Repeat Doses Completed
  13. Phase 1 Drug-drug Interaction Between Belumosudil, Itraconazole, Rifampicin, Rabeprazole, and Omeprazole in Healthy Volunteers Completed
  14. N/A A PH I Pilot Imaging Study to Evaluate Molecular Imaging Methods in HVs and pSS Pts Completed
  15. N/A Exercise Snacks and Glutamine to Improve Glucose Control in Adolescents With Type 1 Diabetes Completed
  16. N/A Mass Evaluation of Lateral Flow Immunoassays for the Detection of SARS-CoV-2 (Covid-19) Antibodies Completed
  17. N/A Epidural Stimulation in Multiple Sclerosis Completed
  18. N/A Vitamin D and Fish Oil for Autoimmune Disease, Inflammation and Knee Pain Completed
  19. N/A Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus Completed

Showing the 25 most-cited and recently-updated of 25 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
cGAS-STING signaling pathway activation drives inflammation, fibrosis, and functional decline in various kidney diseases
Neurology Sys. Review
cGAS-STING signaling pathway activation drives inflammation, fibrosis, and functional decline in various kidney diseases Immune pathway linked to kidney disease progression
This systematic review explores the role of the cGAS-STING signaling pathway in renal pathologies. The authors conclude that this pathway is…
A newly mapped immune pathway may drive kidney damage, opening doors for future treatments.
Frontiers Jun 24, 2026
Astragalus membranaceus derivatives restore immune tolerance and homeostasis in digestive system diseases
Gastroenterology Sys. Review
Astragalus membranaceus derivatives restore immune tolerance and homeostasis in digestive system diseases Astragalus herb shows promise for digestive diseases
This systematic review of 112 studies examines the immunomodulatory mechanisms of Astragalus membranaceus and its derivatives. The authors c…
A review of 112 studies finds Astragalus membranaceus may help restore immune balance in digestive diseases.
Frontiers Jun 17, 2026
scTCR/BCR-seq enables identification of pathogenic clones and informs treatment response in autoimmune diseases
Allergy & Immunology Sys. Review
scTCR/BCR-seq enables identification of pathogenic clones and informs treatment response in autoimmune diseases New Sequencing Methods Help Track Autoimmune Disease Progress
This systematic review examines the utility of scTCR/BCR-seq for analyzing immune cell dynamics in autoimmune disease. The analysis indicate…
Advanced cell sequencing can help doctors track how immune cells behave and predict how patients might respond to specific treatments.
Frontiers Jun 16, 2026
Molecular review explores Siglec signaling pathways in cancer and inflammatory disorders
Allergy & Immunology Sys. Review
Molecular review explores Siglec signaling pathways in cancer and inflammatory disorders Siglec proteins help immune system balance fighting disease and avoiding self-harm
This molecular review examines the role of Siglec signaling pathways in human biology. The authors discuss potential therapeutic opportuniti…
Siglec proteins act as brakes on immune cells, and targeting them could help treat cancer and autoimmune disorders.
Frontiers May 21, 2026
Conceptual framework review discusses metabolic autoimmune neuropsychiatric and oncological disorders without reported trial data
Primary Care & Family Medicine Meta-analysis
Conceptual framework review discusses metabolic autoimmune neuropsychiatric and oncological disorders without reported trial data A new framework helps doctors treat many different health problems
This conceptual framework review addresses metabolic autoimmune neuropsychiatric and oncological disorders. The authors do not report a spec…
This review offers a fresh way to think about treating metabolic, autoimmune, neuropsychiatric, and oncological disorders. It aims to bring …
Frontiers May 18, 2026
Narrative review outlines sialidase biology roadmap for genetic syndromes and inflammatory disorders
Infectious Disease Sys. Review
Narrative review outlines sialidase biology roadmap for genetic syndromes and inflammatory disorders Sialidase Clues Solve Mystery Diseases Doctors Couldn't Explain
This narrative review examines sialidase biology across genetic syndromes, infectious pathogens, inflammatory disorders, autoimmune disorder…
• Sialidase imbalance links rare genetic disorders to common diseases like cancer • Patients with mysterious symptoms getting wrong treatmen…
Frontiers May 12, 2026
Narrative review discusses Treg therapy for non-malignant diseases with noted limitations
Allergy & Immunology Sys. Review
Narrative review discusses Treg therapy for non-malignant diseases with noted limitations Regulatory T cells may soon calm autoimmune diseases safely
This narrative review examines the potential of Regulatory T cell therapy for patients with autoimmune disorders, transplantation-related co…
New immune cells might finally stop the body from attacking itself without dangerous side effects for patients with autoimmune diseases.
Frontiers May 7, 2026
Narrative review discusses CAR-T and HSC therapies for cancer and autoimmune conditions
Oncology Sys. Review
Narrative review discusses CAR-T and HSC therapies for cancer and autoimmune conditions Cancer Cell Therapy Gets Second Life Against Diabetes and MS
This narrative review examines the scope of chimeric antigen receptor T-cell (CAR-T), CAR-engineered regulatory T cell (CAR-Treg), and hemat…
• CAR-T cells trained to calm overactive immune systems show real promise • People with Type 1 diabetes or multiple sclerosis could benefit …
Frontiers May 4, 2026
TNFAIP3 variants show estimated prevalence of 1:2,800 in U.S. autoimmune disease cohorts
Genetics & Precision Medicine Cohort
TNFAIP3 variants show estimated prevalence of 1:2,800 in U.S. autoimmune disease cohorts A hidden genetic cause of autoimmune disease is more common than doctors thought
This cohort study estimated the prevalence of TNFAIP3 loss-of-function and haploprotein-missing variants in U.S.
A specific gene variant linked to autoimmune disease is found in about one in 2,800 people in the U.S.
medRxiv Apr 30, 2026
Review of tissue-resident memory T cell features in cancer and autoimmune diseases
Allergy & Immunology Sys. Review
Review of tissue-resident memory T cell features in cancer and autoimmune diseases New Immune Cells Could Flip Cancer and Autoimmune Treatment
This narrative review examines the developmental differentiation and molecular features of tissue-resident memory T cells within the tumor…
The same immune cells that help fight cancer tumors can also drive autoimmune disease damage, offering a new way to treat both conditions.
Frontiers Apr 21, 2026
Elevated CSF and blood sCD27 associated with autoimmune disease in severe psychiatric disorders and MS
Psychiatry Cohort
Elevated CSF and blood sCD27 associated with autoimmune disease in severe psychiatric disorders and MS Could a simple protein in spinal fluid reveal hidden autoimmune disease in psychiatric patients?
This cohort study measured soluble CD27 (sCD27) in cerebrospinal fluid and blood from patients with severe psychiatric disorders, multiple s…
A simple spinal fluid protein may reveal hidden autoimmune disease in psychiatric patients who show signs of neuroinflammation.
medRxiv Apr 19, 2026
CAR T-cell optimization strategies are reviewed for hematologic cancers, solid tumors, and immune-mediated diseases
Cardiology Sys. Review
CAR T-cell optimization strategies are reviewed for hematologic cancers, solid tumors, and immune-mediated diseases Can fixing CAR T-cells in multiple ways finally make them safer and more effective for cancer patients?
This systematic review evaluates CAR T-cell therapy optimization strategies involving genetic, epigenetic, metabolic, and microenvironmental…
Fixing CAR T-cells across genetics, metabolism, and environment offers a safer, more effective path for treating blood cancers, solid tumors…
Frontiers Apr 9, 2026

Questions about autoimmune disorders

What new treatments for autoimmune diseases are emerging from cancer research?

Cancer research is producing new treatments for autoimmune diseases by adapting cell therapies like CAR-T cells and targeting shared inflammatory pathways such as IRAK4 and mitochondrial transfer.

Full answer →
Can mitochondrial transfer between cells help reduce inflammation in autoimmune diseases?

Mitochondrial transfer between cells can reduce inflammation in autoimmune diseases by reprogramming immune cells to stop overactive responses and calm the immune system.

Full answer →
How might hematopoietic stem cell therapies impact patients with autoimmune diseases?

Hematopoietic stem cell (HSC) therapies can reset the immune system to stop autoimmune attacks, though they carry risks like infection and require careful nutrition and monitoring.

Full answer →
What conditions besides cancer are linked to Siglec signaling pathways?

Siglec signaling pathways are linked to autoimmune and inflammatory disorders, neurodegeneration, and infections in addition to cancer.

Full answer →
Are there therapeutic opportunities for autoimmune disorders in cancer research?

Research shows that targeting shared molecular pathways like Siglec signaling, mitochondrial cell death, and immune metabolism offers new ways to treat both autoimmune disorders and cancer.

Full answer →
How does sialidase biology relate to treating autoimmune disorders?

Sialidase biology relates to autoimmune disorders by regulating immune signals through sialic acid, a process that can be targeted to restore balance in the immune system.

Full answer →
See all 6 questions about autoimmune disorders →

All autoimmune disorders Articles